Specifically, a study about molecular analysis including PAM50 gene expression features of HER2-low BC found that ERBB2 levels are predominant in HR+/HER2-low tumors compared with TNBC/HER2-low tumors [6]. This evidence concerns the gene ERBB2 and breast cancer.